Genialis

📍 Boston, United States🗓 Founded 2015👥 33 employees💰 Last funded Oct 2024
Biotechnology🌐 genialis.com
Website LinkedIn
Genialis, the RNA biomarker company, is creating a world where healthcare delivers the best possible outcomes for patients, their families, and their communities. Genialis develops and validates clinically actionable biomarkers informed by the world’s most ethnographically diverse cancer data sets to better predict patient responses and guide treatment decisions for targeted inhibitors, immunotherapies, and other emerging therapeutic classes. Genialis is trusted by pharma and diagnostics partners, and together, we are transforming medicine through data.
4
Total investors
2
Early stage
1
Mid stage
1
Late stage
2015
Founded

Investors

4 investors
All
Early stage
Mid stage
Late stage
Investor geography3 countries
Switzerland
2
United States
1
Germany
1
Investor activity2017–2024 · investors recorded per year
201722020120241
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Genialis?
Genialis has 4 investors on record on gritt.io, including 2 early-stage backers, 1 mid-stage and 1 late-stage investors.
When did Genialis last raise funding?
The most recent investment in Genialis recorded on gritt.io was in October 2024.
When was Genialis founded?
Genialis was founded in 2015.
What industry is Genialis in?
Genialis operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is Genialis based?
Genialis is headquartered in Boston, United States.